Tariquidar: Phase III

QLTI temporarily suspended enrollment of additional patients for 3 months in 2 ongoing Phase III trials of tariquidar. QLT said that an independent data and safety monitoring committee (DSMC) recommended the suspension because of safety concerns related to certain combinations of tariquidar and chemotherapy. Accrual in the trials had reached the number of patients required for a 3-month interim analysis. The trials will remain halted until all patients already enrolled in the trial have been followed for three months minimum.

At this time, the DSMC will perform another safety review as well as review efficacy. Until then, the DSMC is blinded to efficacy data. ...